The Unmoveable Movement

In a groundbreaking medical achievement, 21-year-old Sebastien Beauzile became the first patient in New York State to be cured of sickle cell disease using an innovative gene therapy. Announced in March 2025, doctors at Cohen Children's Medical Center on Long Island revealed that Beauzile had undergone treatment on December 17, 2024, and had shown no symptoms of the disease since. Beauzile had battled the chronic pain, joint issues, and debilitating skin ulcers caused by sickle cell disease for his entire life. Now, with this new gene therapy, he stands as a living testament to the potential of modern medicine to cure once thought-incurable conditions.

The gene therapy that changed Beauzile’s life is called Lyfgenia, developed by Bluebird Bio. This treatment works by altering a patient's own bone marrow cells to produce healthy hemoglobin, which effectively addresses the root cause of sickle cell disease. According to Dr. Jeffrey Lipton, the director of pediatric hematology at Cohen Children's Medical Center, this therapy is “a fix” for patients suffering from the condition. It marks a significant breakthrough in treating sickle cell disease, which has historically been managed through pain relief and blood transfusions rather than a definitive cure.

Lyfgenia is part of a new generation of gene therapies, including another similar treatment called Casgevy, that received FDA approval in late 2023. In clinical trials, Lyfgenia demonstrated impressive results, with 88% of patients experiencing complete symptom resolution. However, despite its success, the therapy comes at a steep price—around $3.1 million per patient, which has sparked concerns over the long-term accessibility of such life-changing treatments. Sickle cell disease affects over 100,000 Americans, with a disproportionate impact on the Black community, as approximately 90% of patients are Black.

While the development of Lyfgenia and other gene therapies offers hope for many, the high cost of these treatments raises important questions about healthcare equity and access. As medical science advances, the challenge remains to ensure that these groundbreaking therapies are available to all who need them, regardless of their socioeconomic status. Sebastien Beauzile’s story is a beacon of hope for those affected by sickle cell disease, but it also highlights the need for systemic changes to make such therapies accessible to a wider population, ensuring that advancements in medicine benefit everyone.

Pr***en siblings Kali (13) and Spirit Rahman (11) launched Stock Up Kids, a youth-focused brand designed to teach other children about the stock market and financial literacy, according to TheGrio.

Their interest began early when they started learning investing concepts through “paper trading” on a financial app, which lets users practice buying and selling stocks without using real money. That hands-on experience helped them understand how markets work in a simplified, risk-free way.

They later turned what they learned into a teaching platform, creating content aimed at helping other kids understand basics like saving, investing, and long-term wealth building. Their goal with Stock Up Kids is to make financial education more accessible and relatable for younger audiences.

Their story highlights a growing trend of early financial literacy education, where young people are not only learning about money but actively sharing that knowledge with their peers to build long-term financial awareness and independence.